Voyager Therapeutics Inc
Company Profile
Business description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Contact
75 Hayden Avenue
LexingtonMA02421
USAT: +1 857 259-5340
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
172
Stocks News & Analysis
stocks
AI stocks winners, laggards and losers for 2025
stocks
12 picks for an income portfolio - Q4 2025 update
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,092.70 | 25.50 | 0.28% |
| CAC 40 | 8,362.09 | 118.63 | 1.44% |
| DAX 40 | 25,261.64 | 134.18 | 0.53% |
| Dow JONES (US) | 49,504.07 | 237.96 | 0.48% |
| FTSE 100 | 10,124.60 | 79.91 | 0.80% |
| HKSE | 26,551.45 | 319.66 | 1.22% |
| NASDAQ | 23,671.35 | 191.33 | 0.81% |
| Nikkei 225 | 51,939.89 | 822.63 | 1.61% |
| NZX 50 Index | 13,683.29 | 12.96 | -0.09% |
| S&P 500 | 6,966.28 | 44.82 | 0.65% |
| S&P/ASX 200 | 8,759.40 | 25.80 | 0.30% |
| SSE Composite Index | 4,161.89 | 41.46 | 1.01% |